Acute coronary syndrome and recurrent colitis as immune-related adverse events in a lung cancer patient

Immune checkpoint inhibitors have become a target for pharmacological research in lung cancer. Immune-related adverse events (irAEs) such as pneumonitis, colitis, hepatitis and endocrinopathies have been well characterized in immune checkpoint inhibitors, but coronary toxicities, like acute coronary...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 2020-01, Vol.26 (1), p.252-255
Main Authors: Cancela-Díez, Bárbara, Gómez-De Rueda, Félix, Antolinos Pérez, María J, Jiménez-Morales, Alberto, López-Hidalgo, Javier L
Format: Article
Language:English
Subjects:
Acute Coronary Syndrome - chemically induced
Acute coronary syndromes
Aged
Antineoplastic Agents, Immunological - adverse effects
Colitis
Colitis - chemically induced
Endocrine disorders
Hepatitis
Humans
Immune checkpoint inhibitors
Immunotherapy
Inflammatory bowel disease
Inhibitors
Lung cancer
Lung Neoplasms - drug therapy
Male
Monoclonal antibodies
Nivolumab - adverse effects
Pneumonitis
Recurrence
Targeted cancer therapy
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors have become a target for pharmacological research in lung cancer. Immune-related adverse events (irAEs) such as pneumonitis, colitis, hepatitis and endocrinopathies have been well characterized in immune checkpoint inhibitors, but coronary toxicities, like acute coronary syndrome, are poorly described. Herein, we report a possible acute coronary syndrome as immune-related adverse event in a lung cancer patient.
ISSN:1078-1552
1477-092X
DOI:10.1177/1078155219865596